Using AKT as a therapeutic target has been a focus of study for many cancers [52] including gliomas [53] due to its pivotal role in regulating apoptosis and autophagy [54,55]; however, its use is complicated by the fact that there are three AKT isoforms (AKT1, AKT2, AKT3), which are functionally distinct despite sharing a great deal of sequence homology [56-59]. The gene discussed is AKT1; the disease is central nervous system cancer.